Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Insight, 2024

This “Chronic Inflammatory Demyelinating Polyneuropathy- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Inflammatory Demyelinating Polyneuropathy: Understanding

Chronic Inflammatory Demyelinating Polyneuropathy: Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is an autoimmune-mediated inflammatory disease affecting the peripheral nerves and the nerve roots. This disorder is characterized by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibres) of the peripheral nerves and by immune infiltrates. The disorder causes progressive motor and sensory deficits that manifest as proximal and distal muscle weakness, numbness, paraesthesia, sensory ataxia, and often severe disability, which hallmark severe demyelination and secondary axonal loss of peripheral nerves. CIDP has a slow onset with continued progression over more than two months and typically evolves as a relapsing, progressive, or monophasic disorder.

The pathogenesis of CIDP remains largely unknown. Immuno-mediated inflammatory mechanisms have been postulated, with a pivotal involvement of macrophages and proteases, they secrete oxygen reactive species, cytokines, and T lymphocytes. The implication of autoantibodies has also been proposed. Effectively, CIDP can follow various infections, including Campylobacter jejuni, which is, however, more frequently associated with Guillain-Barré syndrome (GBS), an inflammatory neuropathy sharing major features with CIDP. Studies have demonstrated molecular similarity between a component of Campylobacter jejuni and GM1, one of the targets of the autoantibodies found in patients, suggesting a role of molecular mimicry by foreign epitopes in the pathogenesis of the disease. The deposition of autoantibodies at peripheral nerve components could trigger the phagocytosis of myelin by macrophages via the recognition of immunoglobulin (Ig) fragment crystallizable receptor (FcR), for example, leading to the activation of the complement cascade and resulting axonal damage. Antibodies to LM1, a ganglioside localized in peripheral nerve myelin, and LM1-containing ganglioside complexes, or pathogenic IgG4 autoantibodies to nodal or paranodal junction proteins, such as neurofascin 155 and 186, gliomedin, and contactin 1, have been described in CIDP. However, their low prevalence, in a minority of patients with CIDP precludes them from being considered as possible biomarkers and does not permit to elaborate pathophysiological consideration based on the antigens they target. The prognosis is variable and depends on age, the clinical course, responsiveness to treatment, and electrophysiological findings.

Chronic Inflammatory Demyelinating Polyneuropathy- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape is provided which includes the disease overview and Chronic Inflammatory Demyelinating Polyneuropathy treatment guidelines. The assessment part of the report embraces, in depth Chronic Inflammatory Demyelinating Polyneuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Inflammatory Demyelinating Polyneuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Inflammatory Demyelinating Polyneuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Inflammatory Demyelinating Polyneuropathy.

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs Chapters

This segment of the Chronic Inflammatory Demyelinating Polyneuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs

HYQVIA: Takeda HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It contains immunoglobulins collected from human plasma. The drug is infused under the skin into the fatty subcutaneous tissue. The hyaluronidase part of HYQVIA helps more of the Ig get absorbed into the body. The drug is approved for adults with primary immunodeficiency, and in adults, children and adolescents with PI and with secondary immunodeficiency. While it is in Phase III trial forCIDP.

Rozanolixizumab: UCB S.A.Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to the human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and Immunoglobulin G (IgG), accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies. The drug is under clinical development with the aim of improving the lives of people with pathogenic IgG-autoantibody-driven autoimmune diseases, including ITP, myasthenia gravis (MG), and CIDP, by driving the removal of pathogenic IgG autoantibodies.

Temelimab: Ge Neuro SATemelimab is a monoclonal antibody designed to neutralize a pathogenic viral envelope protein, encoded by a member of the Human Endogenous Retrovirus-W family, p HERV-W. This protein is thought to be a causal factor in several diseases, including multiple sclerosis, Type 1 diabetes and CIDP. It neutralizes the p HERV-W Env protein without targeting the patient's immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease's progress in all its forms. By neutralizing pHERV-W env, GNbAC1 could at the same time block these pathological inflammatory processes and restore remyelination in patients. The drug is currently in Phase I trial for the treatmentofCIDPpatients.

Chronic Inflammatory Demyelinating Polyneuropathy: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Inflammatory Demyelinating Polyneuropathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Inflammatory Demyelinating Polyneuropathy

There are approx. 10+ key companies which are developing the therapies for Chronic Inflammatory Demyelinating Polyneuropathy. The companies which have their Chronic Inflammatory Demyelinating Polyneuropathy drug candidates in the most advanced stage, i.e. phase III include, Takeda.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Inflammatory Demyelinating Polyneuropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Inflammatory Demyelinating Polyneuropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Inflammatory Demyelinating Polyneuropathy drugs.

Chronic Inflammatory Demyelinating Polyneuropathy Report Insights

• Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Inflammatory Demyelinating Polyneuropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Inflammatory Demyelinating Polyneuropathy drugs?
• How many Chronic Inflammatory Demyelinating Polyneuropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Inflammatory Demyelinating Polyneuropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Inflammatory Demyelinating Polyneuropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda
• Sanofi
• Johnson & Johnson Services
• Immunovant
• UCB S.A.
• GeNeuro
• Nanjing IASO Biotherapeutics
• Bioasis Technologies, Inc.

Key Products

• HYQVIA
• SAR445088
• Nipocalimab
• Rozanolixizumab
• Batoclimab
• Temelimab
• CT103A
• CRES-101

This product will be delivered within 1-3 business days.